FAOD
MCID: FTT003
MIFTS: 39

Fatty Acid Oxidation Disorders (FAOD) malady

Categories: Genetic diseases

Aliases & Classifications for Fatty Acid Oxidation Disorders

Aliases & Descriptions for Fatty Acid Oxidation Disorders:

Name: Fatty Acid Oxidation Disorders 24
Faod 24

Classifications:



Summaries for Fatty Acid Oxidation Disorders

MalaCards based summary : Fatty Acid Oxidation Disorders, also known as faod, is related to trifunctional protein deficiency and carnitine-acylcarnitine translocase deficiency. An important gene associated with Fatty Acid Oxidation Disorders is SLC25A20 (Solute Carrier Family 25 Member 20), and among its related pathways/superpathways are Metabolism and Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha). The drugs Metformin and insulin have been mentioned in the context of this disorder. Affiliated tissues include liver, skin and testes, and related phenotypes are homeostasis/metabolism and liver/biliary system

Related Diseases for Fatty Acid Oxidation Disorders

Diseases related to Fatty Acid Oxidation Disorders via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 39)
id Related Disease Score Top Affiliating Genes
1 trifunctional protein deficiency 11.3
2 carnitine-acylcarnitine translocase deficiency 11.1
3 d-bifunctional protein deficiency 11.0
4 acyl-coa dehydrogenase, short-chain, deficiency of 11.0
5 vitamin metabolic disorder 10.2 ACADM ACADVL
6 myxozoa 10.2 ACADVL CPT2
7 hermansky-pudlak syndrome 9 10.2 ACADM ACADS
8 malignant cardiac peripheral nerve sheath neoplasm 10.2 ACADM HADHA
9 deafness, autosomal dominant 52 10.1 ACADVL CPT2 SLC25A20
10 maple syrup urine disease, mild variant 10.1 ACADM ACADVL HADHA
11 zygodactyly 1 10.1 CPT1A CPT2 SLC25A20
12 obesity, morbid, due to leptin receptor deficiency 10.1 ACADM ACADVL HADHA
13 retinitis pigmentosa 4, autosomal dominant or recessive 10.1 ACADM ACADVL
14 waldenstrom macroglobulinemia 10.1 ACADVL SLC25A13
15 pancreatic cancer 1 10.1 ACADM ACADVL CPT2
16 subleukemic leukemia 10.1 ACADM PPARA
17 b-cell childhood acute lymphoblastic leukemia 10.1 ACADVL CPT2
18 mitochondrial phosphate carrier deficiency 10.0 ACADM ACADS SLC25A13
19 carnitine acetyltransferase deficiency 10.0 PPARA SLC25A13
20 pain disorder 10.0 ACADM ACADS
21 spinocerebellar ataxia, autosomal recessive 13 9.9 HSD17B4 SCP2
22 short-rib thoracic dysplasia 13 with or without polydactyly 9.9 HSD17B4 SCP2
23 inflammatory bowel disease 18 9.9 HSD17B4 SCP2
24 heimler syndrome 1 9.9 HSD17B4 SCP2
25 3-hydroxyacyl-coa dehydrogenase deficiency 9.8
26 liver disease 9.8
27 organic acidemia 9.8
28 lymphoid leukemia 9.8 HADHA PPARA SLC25A13
29 encephalopathy, acute, infection-induced, 4 9.8 ACADL ACADVL CPT1A CPT2 SLC25A20
30 van maldergem syndrome 9.8 ACADL ACADVL CPT1A CPT2 SLC25A20
31 acute insulin response 9.8 ACADL ACADM ACADS ACADVL HADHA
32 atrial fibrillation, familial, 4 9.8 ACADL ACADM ACADVL SLC25A13 SLC25A20
33 mental retardation, autosomal recessive 44 9.7 HSD17B4 PPARA SCP2
34 cyclic vomiting syndrome 9.7
35 sudden infant death syndrome 9.7
36 hellp syndrome 9.7
37 reye syndrome 9.7
38 cystinosis, ocular nonnephropathic 9.5 ACADL ACADS ACADVL CPT2 HADHA SLC25A13
39 fibular hypoplasia 8.5 ACADL ACADM ACADS ACADVL CPT1A CPT2

Graphical network of the top 20 diseases related to Fatty Acid Oxidation Disorders:



Diseases related to Fatty Acid Oxidation Disorders

Symptoms & Phenotypes for Fatty Acid Oxidation Disorders

MGI Mouse Phenotypes related to Fatty Acid Oxidation Disorders:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.03 SLC25A20 ACADS ACADVL CPT1A CPT2 HADHA
2 liver/biliary system MP:0005370 9.81 ACADS ACADVL HADHA HSD17B4 PPARA ACADL
3 mortality/aging MP:0010768 9.7 SLC25A13 SLC25A20 ACADS ACADVL CPT1A CPT2
4 muscle MP:0005369 9.1 ACADM ACADS ACADVL HADHA HSD17B4 PPARA

Drugs & Therapeutics for Fatty Acid Oxidation Disorders

Drugs for Fatty Acid Oxidation Disorders (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 159)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
2 insulin Phase 4,Phase 2,Phase 1
3 Hypoglycemic Agents Phase 4,Phase 2,Phase 3,Phase 1
4 Hypolipidemic Agents Phase 4,Phase 3,Phase 2
5 Insulin, Globin Zinc Phase 4,Phase 2,Phase 1
6 Lipid Regulating Agents Phase 4,Phase 3,Phase 2
7 Antimetabolites Phase 4,Phase 3,Phase 2
8 Hormones Phase 4,Phase 2,Phase 3,Phase 1
9 Pharmaceutical Solutions Phase 4,Phase 2
10 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
11 Anticholesteremic Agents Phase 4
12 Liver Extracts Phase 4
13 Calcium, Dietary Phase 4
14 Atorvastatin Calcium Phase 4 134523-03-8
15
Bezafibrate Approved Phase 3,Phase 2 41859-67-0 39042
16 ACIPIMOX Phase 2, Phase 3
17 glucagon Phase 2, Phase 3
18 Gastrointestinal Agents Phase 2, Phase 3
19 Glucagon-Like Peptide 1 Phase 2, Phase 3,Phase 1
20 Hormone Antagonists Phase 2, Phase 3
21 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
22 Protective Agents Phase 2, Phase 3
23 Incretins Phase 2, Phase 3
24 Antioxidants Phase 2, Phase 3
25 carnitine Nutraceutical Phase 3,Phase 2
26 Cranberry Nutraceutical Phase 2, Phase 3
27 Omega 3 Fatty Acid Nutraceutical Phase 3,Phase 2
28
Fenofibrate Approved Phase 2 49562-28-9 3339
29
Glycerol Approved, Experimental Phase 2 56-81-5 753
30
Trimetazidine Approved Phase 2 5011-34-7
31 Vasodilator Agents Phase 2
32 Flax Nutraceutical Phase 2
33 Linoleate Nutraceutical Phase 2
34
Canagliflozin Approved Phase 1 842133-18-0
35
Benzocaine Approved Phase 1 1994-09-7, 94-09-7 2337
36 tannic acid Approved, Nutraceutical Phase 1
37
Palmitic Acid Experimental Phase 1 57-10-3 985
38 Dipeptidyl-Peptidase IV Inhibitors Phase 1
39 Peripheral Nervous System Agents Phase 1
40 Central Nervous System Depressants Phase 1
41 Anesthetics Phase 1
42 Anesthetics, Local Phase 1
43
Pioglitazone Approved, Investigational 111025-46-8 4829
44
Iron Approved 7439-89-6 23925
45
Amoxicillin Approved, Vet_approved 26787-78-0 33613 2171
46
Vancomycin Approved 1404-90-6 441141 14969
47
Ethanol Approved 64-17-5 702
48
Heparin Approved, Investigational 9005-49-6 772 46507594
49
Dopamine Approved 51-61-6, 62-31-7 681
50
Simvastatin Approved 79902-63-9 54454

Interventional clinical trials:

(show top 50) (show all 110)
id Name Status NCT ID Phase
1 Effects of Metformin on Hepatic FFA Metabolism Completed NCT01729156 Phase 4
2 Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly Recruiting NCT02115906 Phase 4
3 Is Myopathy Part of Statin Therapy (IMPOSTER-16) Terminated NCT00127335 Phase 4
4 Bezafibrate Trial in CPT2 Deficiency Unknown status NCT00336167 Phase 3
5 Efficacy Study of Metformin Glycinate on Postprandial Lipemia Unknown status NCT02064881 Phase 2, Phase 3
6 Go Fish: Omega-3 Fatty Acid Supplementation in Diabetes-Related Kidney Disease Completed NCT01092390 Phase 3
7 Effects of n-3 Polyunsaturated Fatty Acids and Antioxidants on Postprandial Hyperlipidemia and Vascular Function in Men Completed NCT00296595 Phase 2, Phase 3
8 Modulation of Human Myocardial Metabolism by GLP-1 Dose Response Completed NCT01607450 Phase 2, Phase 3
9 The Impact of Free Fatty Acid (FFA-) Suppression on Myocardial Lipids and Function in Patients With Type 2 Diabetes Completed NCT01980524 Phase 2, Phase 3
10 The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure Terminated NCT00944229 Phase 3
11 High Protein Diet in Patients With Long-chain Fatty Acid Oxidation Disorders Completed NCT01494051 Phase 1, Phase 2
12 Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder Completed NCT01379625 Phase 2
13 An Open-label Phase 2 Study of UX007 (Triheptanoin) in Subjects With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Completed NCT01886378 Phase 2
14 Substrate Cycling in Energy Metabolism Completed NCT00361751 Phase 2
15 Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects Completed NCT00983788 Phase 2
16 Effect of Pulse Fractions on Indices on Cardiovascular Disease and Diabetes Risk Factors Completed NCT00839774 Phase 2
17 Efficacy of High-oleic Canola and Flaxseed Oils for Hypercholesterolemia and Cardiovascular Disease Risk Factors Completed NCT00927199 Phase 2
18 The Effects of L-carnitine on Fatigue in Spinal Cord Injury Completed NCT01232907 Phase 2
19 A Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT2104 Capsules Administered for 28 Days to Subjects With Type 2 Diabetes Mellitus Completed NCT01018017 Phase 2
20 Trimetazidine in Pulmonary Artery Hypertension Recruiting NCT02102672 Phase 2
21 The Effects of NOx and Conjugated Linoleic Acid on Asthmatics With the Metabolic Syndrome Recruiting NCT02433977 Phase 2
22 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies. Enrolling by invitation NCT02214160 Phase 2
23 Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients Terminated NCT02274740 Phase 2
24 Differential Metabolism of Dietary Fatty Acids Completed NCT00059254 Phase 1
25 Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Completed NCT02009488 Phase 1
26 Impact of a Ketogenic Diet Intervention During Radiotherapy on Body Composition Recruiting NCT02516501 Phase 1
27 Nutrient Sensing in the Duodenum Enrolling by invitation NCT01694004 Phase 1
28 Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans Unknown status NCT01165190
29 Effects of Carnitine on Oxidative Stress to IVIR Administration to CKD Patients:Impact of Haptoglobin Genotype Unknown status NCT02312414
30 The Importance of the Gut Microbiota in Body Weight Control and Insulin Sensitivity Unknown status NCT02241421
31 Fatty Acid Oxidation Disorders & Body Weight Regulation Grant Completed NCT00654004
32 Nutritional Therapy of the Deficits of Oxidation Mitochondrial of the Fatty Acids Completed NCT00328159
33 Fat Induced Insulin Resistance and Atherosclerosis Completed NCT02348190
34 Fat and Sugar Metabolism During Exercise, With and Without L-carnitine in Patients With Carnitine Transporter Deficiency Completed NCT02226419
35 Energy Requirements in Mitochondrial Disease Completed NCT01776918
36 Effect of Caloric Restriction on Fat Oxidation in Obese Men and Women (Magellan II) Completed NCT01616082
37 Moderate Alcohol Consumption, Fat and Carbohydrate Metabolism and Insulin Sensitivity Completed NCT00364767
38 Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome Completed NCT00656851
39 Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During Fasting Completed NCT02500095
40 Fat Metabolism in Pregnancy and Neonatal Heart Function in Diabetes Completed NCT01346527
41 CCRC: Understanding the Effects of Omega-3 Fatty Acids Versus Lignans in Flaxseed on Metabolic and Inflammatory Markers Leading to Diabetes and Cardiovascular Disease Completed NCT00935922
42 Effects of Parenteral L-carnitine Supplementation in Premature Neonates Completed NCT00841295
43 Body Composition and Very-Low-Density-Lipoprotein-Triglycerides (VLDL-TG) Kinetics Completed NCT00646698
44 Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome Completed NCT01511016
45 Ursodeoxycholic Acid in Bariatric Surgery Completed NCT01548079
46 Do Apolipoprotein E Polymorphisms Influence Risk of Cognitive Decline by Modulating Omega-3 Fatty Acid Metabolism? Completed NCT01577004
47 Evaluating the Roles of Estrogen and Progesterone in Heart Metabolism Completed NCT00565916
48 Canola Oil Multicentre Intervention Trial (COMIT) Completed NCT01233778
49 Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation Completed NCT00470262
50 Rectal Short Chain Fatty Acids Combinations and Substrate and Energy Metabolism Completed NCT01983046

Search NIH Clinical Center for Fatty Acid Oxidation Disorders

Genetic Tests for Fatty Acid Oxidation Disorders

Genetic tests related to Fatty Acid Oxidation Disorders:

id Genetic test Affiliating Genes
1 Fatty Acid Oxidation Disorders 24

Anatomical Context for Fatty Acid Oxidation Disorders

MalaCards organs/tissues related to Fatty Acid Oxidation Disorders:

39
Liver, Skin, Testes, Placenta, Skeletal Muscle, Whole Blood

Publications for Fatty Acid Oxidation Disorders

Articles related to Fatty Acid Oxidation Disorders:

(show top 50) (show all 75)
id Title Authors Year
1
Impact of fatty acid oxidation disorders in child neurology: from Reye syndrome to Pandora's box. ( 25761966 )
2015
2
Should the beneficial impact of bezafibrate on fatty acid oxidation disorders be questioned? ( 25310995 )
2014
3
Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial. ( 24453079 )
2014
4
Clinical study of organic acidemias and fatty acid oxidation disorders detected in adults. ( 23524598 )
2013
5
Neuropsychological outcomes in fatty acid oxidation disorders: 85 cases detected by newborn screening. ( 23798014 )
2013
6
Pathophysiology of fatty acid oxidation disorders and resultant phenotypic variability. ( 23674167 )
2013
7
Fatty Acid oxidation disorders in a chinese population in taiwan. ( 23700290 )
2013
8
The effect of valinomycin in fibroblasts from patients with fatty acid oxidation disorders. ( 23867825 )
2013
9
Muscle MRI in patients with long-chain fatty acid oxidation disorders. ( 24305961 )
2013
10
[Acute fatty liver in pregnancy: revealing fetal fatty acid oxidation disorders]. ( 22325456 )
2012
11
Variability in the clinical management of fatty acid oxidation disorders: results of a survey of Canadian metabolic physicians. ( 21630065 )
2012
12
Bezafibrate can be a new treatment option for mitochondrial fatty acid oxidation disorders: evaluation by in vitro probe acylcarnitine assay. ( 22841441 )
2012
13
Rubratoxin B induces signs of fatty acid oxidation disorders (FAODs) in mice. ( 21835235 )
2011
14
Fatty acid omega-oxidation as a rescue pathway for fatty acid oxidation disorders in humans. ( 21156023 )
2011
15
Current issues regarding treatment of mitochondrial fatty acid oxidation disorders. ( 20830526 )
2010
16
ESI-MS/MS measurement of free carnitine and its precursor I^-butyrobetaine in plasma and dried blood spots from patients with organic acidurias and fatty acid oxidation disorders. ( 20637671 )
2010
17
Mitochondrial fatty acid oxidation disorders: pathophysiological studies in mouse models. ( 20532823 )
2010
18
Mitochondrial fatty acid oxidation disorders. Proceedings of an international symposium. October 2008. Fulda, Germany. ( 21275107 )
2010
19
Fatty acid oxidation disorders: outcome and long-term prognosis. ( 20049534 )
2010
20
Clinical and biochemical monitoring of patients with fatty acid oxidation disorders. ( 20066495 )
2010
21
Update on mitochondrial fatty acid oxidation disorders. ( 20842433 )
2010
22
Pathophysiology of fatty acid oxidation disorders. ( 20824345 )
2010
23
Fatty acid oxidation disorders: maternal health and neonatal outcomes. ( 19926542 )
2010
24
Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening. ( 20449660 )
2010
25
Deuterated palmitate-driven acylcarnitine formation by whole-blood samples for a rapid diagnostic exploration of mitochondrial fatty acid oxidation disorders. ( 19422814 )
2009
26
Mitochondrial fatty-acid oxidation disorders. ( 18708005 )
2008
27
PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders. ( 18392740 )
2008
28
[Application of tandem mass spectrometry on the diagnosis of fatty acid oxidation disorders]. ( 18067086 )
2007
29
ESI-MS/MS study of acylcarnitine profiles in urine from patients with organic acidemias and fatty acid oxidation disorders. ( 17301002 )
2007
30
A retrospective ESI-MS/MS analysis of newborn blood spots from 18 symptomatic patients with organic acid and fatty acid oxidation disorders diagnosed either in infancy or in childhood. ( 17641825 )
2007
31
3-hydroxyacyl-CoA dehydrogenase (HAD) deficiency replaces short-chain hydroxyacyl-CoA dehydrogenase (SCHAD) deficiency as well as medium- and short-chain hydroxyacyl-CoA dehydrogenase (M/SCHAD) deficiency as the consensus name of this fatty acid oxidation disorder. ( 17434778 )
2007
32
Differentiation of long-chain fatty acid oxidation disorders using alternative precursors and acylcarnitine profiling in fibroblasts. ( 16297647 )
2006
33
Potential of fibrates in the treatment of fatty acid oxidation disorders: revival of classical drugs? ( 16763897 )
2006
34
The association between acute fatty liver of pregnancy and fatty acid oxidation disorders. ( 15673650 )
2005
35
Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders. ( 16115821 )
2005
36
Identification of fatty acid oxidation disorder patients with lowered acyl-CoA thioesterase activity in human skin fibroblasts. ( 15638818 )
2005
37
Fatty acid oxidation disorder as a cause of sudden infant death syndrome (SIDS)--a case report. ( 16366103 )
2005
38
Lack of correlation between fatty acid oxidation disorders and haemolysis, elevated liver enzymes, low platelets (HELLP) syndrome? ( 15858960 )
2005
39
Fetal fatty acid oxidation disorders, their effect on maternal health and neonatal outcome: impact of expanded newborn screening on their diagnosis and management. ( 15817498 )
2005
40
Implications of impaired ketogenesis in fatty acid oxidation disorders. ( 14769488 )
2004
41
Mitochondrial trifunctional protein deficiency: a severe fatty acid oxidation disorder with cardiac and neurologic involvement. ( 12838198 )
2003
42
Selective screening for fatty acid oxidation disorders by tandem mass spectrometry: difficulties in practical discrimination. ( 12828998 )
2003
43
Human placenta metabolizes fatty acids: implications for fetal fatty acid oxidation disorders and maternal liver diseases. ( 12582009 )
2003
44
Incidence and short-term outcome of children with symptomatic presentation of organic acid and fatty acid oxidation disorders in Germany. ( 12456920 )
2002
45
Management of fatty acid oxidation disorders: a survey of current treatment strategies. ( 12487544 )
2002
46
Postmortem screening for fatty acid oxidation disorders by analysis of Guthrie cards with tandem mass spectrometry in sudden unexpected death in infancy. ( 12461502 )
2002
47
Fatty acid oxidation disorders. ( 11826276 )
2002
48
Mitochondrial fatty acid oxidation disorders in Thai infants: a report of 3 cases. ( 12403251 )
2002
49
A method for quantitative acylcarnitine profiling in human skin fibroblasts using unlabelled palmitic acid: diagnosis of fatty acid oxidation disorders and differentiation between biochemical phenotypes of MCAD deficiency. ( 12385891 )
2002
50
Prevalent mutations in fatty acid oxidation disorders: diagnostic considerations. ( 11216903 )
2000

Variations for Fatty Acid Oxidation Disorders

Expression for Fatty Acid Oxidation Disorders

Search GEO for disease gene expression data for Fatty Acid Oxidation Disorders.

Pathways for Fatty Acid Oxidation Disorders

Pathways related to Fatty Acid Oxidation Disorders according to GeneCards Suite gene sharing:

(show all 18)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 ACADL ACADM ACADS ACADVL CPT1A CPT2
2
Show member pathways
12.68 ACADL ACADM ACADS ACADVL CPT1A CPT2
3
Show member pathways
12.05 ACADM ACADS HADHA
4 11.91 ACADM CPT1A HADHA
5
Show member pathways
11.76 ACADM ACADS HADHA
6
Show member pathways
11.59 ACADL ACADM ACADS ACADVL HADHA
7 11.49 ACADL ACADM CPT1A CPT2 PPARA SCP2
8
Show member pathways
11.46 ACADL ACADM ACADS ACADVL CPT1A CPT2
9
Show member pathways
11.38 ACADL HSD17B4 SCP2
10 11.28 ACADM ACADVL CPT1A
11
Show member pathways
11.22 HSD17B4 SCP2
12
Show member pathways
11.15 ACADS HADHA
13 11.13 ACADM CPT1A CPT2 PPARA SCP2
14
Show member pathways
11.08 ACADM HADHA
15 11.04 ACADM HADHA
16
Show member pathways
11 ACADL ACADM ACADS ACADVL CPT1A CPT2
17 10.65 CPT1A CPT2 SLC25A20
18
Show member pathways
10.49 ACADM HADHA

GO Terms for Fatty Acid Oxidation Disorders

Cellular components related to Fatty Acid Oxidation Disorders according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 mitochondrial matrix GO:0005759 9.46 ACADL ACADM ACADS ACADVL
2 mitochondrial inner membrane GO:0005743 9.43 ACADVL CPT1A CPT2 HADHA SLC25A13 SLC25A20
3 mitochondrion GO:0005739 9.36 ACADL ACADM ACADS ACADVL CPT1A CPT2
4 mitochondrial nucleoid GO:0042645 9.32 ACADVL HADHA
5 peroxisomal matrix GO:0005782 9.26 HSD17B4 SCP2

Biological processes related to Fatty Acid Oxidation Disorders according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.91 ACADL ACADM ACADS ACADVL HADHA HSD17B4
2 metabolic process GO:0008152 9.85 ACADL ACADM ACADS ACADVL HADHA SCP2
3 lipid metabolic process GO:0006629 9.81 ACADL ACADM ACADS ACADVL CPT1A CPT2
4 regulation of lipid metabolic process GO:0019216 9.71 ACADM CPT1A CPT2 PPARA
5 fatty acid metabolic process GO:0006631 9.61 ACADL ACADM ACADS ACADVL CPT1A CPT2
6 response to cold GO:0009409 9.58 ACADM ACADVL
7 bile acid biosynthetic process GO:0006699 9.58 HSD17B4 SCP2
8 temperature homeostasis GO:0001659 9.57 ACADL ACADVL
9 fatty acid beta-oxidation using acyl-CoA oxidase GO:0033540 9.56 HSD17B4 SCP2
10 alpha-linolenic acid metabolic process GO:0036109 9.55 HSD17B4 SCP2
11 negative regulation of fatty acid biosynthetic process GO:0045717 9.54 ACADL ACADVL
12 regulation of cholesterol metabolic process GO:0090181 9.52 ACADL ACADVL
13 positive regulation of fatty acid beta-oxidation GO:0032000 9.51 CPT1A PPARA
14 carnitine shuttle GO:0006853 9.5 CPT1A CPT2 SLC25A20
15 carnitine metabolic process GO:0009437 9.49 ACADM CPT1A
16 negative regulation of fatty acid oxidation GO:0046322 9.48 ACADL ACADVL
17 carnitine metabolic process, CoA-linked GO:0019254 9.46 ACADL ACADM
18 fatty acid beta-oxidation using acyl-CoA dehydrogenase GO:0033539 9.43 ACADL ACADM ACADVL
19 fatty acid beta-oxidation GO:0006635 9.23 ACADL ACADM ACADS ACADVL CPT1A CPT2

Molecular functions related to Fatty Acid Oxidation Disorders according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.8 ACADL ACADM ACADS ACADVL HADHA HSD17B4
2 transferase activity, transferring acyl groups GO:0016746 9.65 CPT1A CPT2 SCP2
3 3-hydroxyacyl-CoA dehydrogenase activity GO:0003857 9.46 HADHA HSD17B4
4 flavin adenine dinucleotide binding GO:0050660 9.46 ACADL ACADM ACADS ACADVL
5 carnitine O-palmitoyltransferase activity GO:0004095 9.43 CPT1A CPT2
6 fatty-acyl-CoA binding GO:0000062 9.43 ACADL HADHA SCP2
7 long-chain-acyl-CoA dehydrogenase activity GO:0004466 9.4 ACADL ACADVL
8 long-chain-enoyl-CoA hydratase activity GO:0016508 9.37 HADHA HSD17B4
9 oxidoreductase activity, acting on the CH-CH group of donors GO:0016627 9.26 ACADL ACADM ACADS ACADVL
10 acyl-CoA dehydrogenase activity GO:0003995 8.92 ACADL ACADM ACADS ACADVL

Sources for Fatty Acid Oxidation Disorders

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....